Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer

Chimeric inhibitors, which merge two drug pharmacophores in a single molecule have become a prominent approach for the design of novel anticancer compounds. Here, we examined animacroxam, which combines histone deacetylase (HDAC) inhibitory and cytoskeleton‐interfering pharmacophores, in testicular...

Full description

Bibliographic Details
Main Authors: Gustav Steinemann, Alexandra Dittmer, Jacob Schmidt, David Josuttis, Michael Fähling, Bernhard Biersack, Nicola Beindorff, Eva Jolante Koziolek, Rainer Schobert, Winfried Brenner, Thomas Müller, Bianca Nitzsche, Michael Höpfner
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Molecular Oncology
Subjects:
Online Access:https://doi.org/10.1002/1878-0261.12582